Bristol -Myers Squibb News

Bristol-Myers Squibb and ZymoGenetics Present Final Phase 1b Results for PEG-Interferon Lambda in Hepatitis C

Exelixis Announces Third Quarter 2009 Financial Results

Gary Ginsberg and John Damonti Join Malaria No More Board of Directors

Reuters - 24 minutes ago
Experts in Media and Philanthropy Determined To End Malaria Deaths by 2015 NEW YORK, Oct. 29 /PRNewswire-USNewswire/ -- Malaria No More welcomed two new members of its Board of Directors this week ...

Bristol Myers (BMY) Trading Near 52-Week High

Market Intelligence Center - 54 minutes ago
Bristol Myers (NYSE: BMY) closed yesterday at $22.16. So far the stock has hit a 52-week low of $17.23 and 52-week high of $23.98. Bristol Myers stock has been showing support around 21.77 and ...

Bristol-Myers Squibb Donation to Benefit Students at The Pennington School and Beyond

Business Wire - 4 minutes ago
PENNINGTON, NJ--(BUSINESS WIRE)--Students at The Pennington School will have an unprecedented opportunity this year to conduct hands-on, high-tech science projects, thanks to sophisticated science ...

MEAD JOHNSON NUTRITI Reports Operating Results (10-Q)

GuruFocus.com - 46 minutes ago
Mead Johnson Nutrition Company is a pediatric nutrition company. It manufactures distributes and sells infant formulas and other nutritional products worldwide primarily under the `Enfa` family of ...

Updated NCCN Guidelines for Breast Cancer Discourages Prophylactic Mastectomy in Women Other Than Those at High Risk

CBI Announces FDA Participation at Upcoming Forum on Clinical Trial Investigator Portals

SAFE-BioPharma Receives Safe Harbor Certification

Reuters - 31 minutes ago
FT. LEE, NJ--(Business Wire)-- SAFE-BioPharma Association has certified compliance with the US Department of Commerce and European Union Safe Harbor requirements for the protection of personal ...

ZGEN: To Receive $70M Milestone from Initiation of Phase 2 Hepatitis C Trial

Trading Markets - 2 hours ago
ZymoGenetics, Inc. (ZGEN) announced the initiation of a Phase 2 clinical trial of PEG-Interferon lambda (IL-29) and ribavirin in treatment-naive patients with chronic hepatitis C virus (HCV ...